Muñoz Gonzalo, Alió Jorge L, Montés-Micó Robert, Albarrán-Diego César, Belda José I
Refractive Surgery Department, Instituto Oftalmológico de Alicante, Alicante, Spain.
J Cataract Refract Surg. 2005 Feb;31(2):308-17. doi: 10.1016/j.jcrs.2004.05.056.
To evaluate safety, efficacy, predictability, stability, complications, and patient satisfaction after Artisan phakic intraocular lens (IOL) implantation followed by laser in situ keratomileusis (LASIK) for the correction of high hyperopia.
Instituto Oftalmólogico de Alicante, Alicante, Spain.
This prospective trial included 39 eyes with a mean preoperative spherical equivalent (SE) of 7.39 diopters (D) +/- 1.30 (SD) and a cylinder between 0 and -4.25 D. The Artisan iris-fixated phakic IOL (Ophtec) for hyperopia was implanted, and LASIK was performed 6 to 8 months later. The best corrected visual acuity (BCVA), uncorrected visual acuity (UCVA), refraction, endothelial cell loss (ECL), endothelium morphologic analysis, and patient satisfaction were recorded. The minimum follow-up was 12 months.
At 1 year, 37 eyes (94.9%) were within +/-1.00 D of emmetropia and 31 eyes (79.5%) were within +/-0.50 D. Thirty-five eyes (89.7%) achieved a UCVA of 0.5 or better. There was a statistically significant decrease in BCVA after phakic IOL implantation, but this effect was corrected after LASIK. Nine eyes (23.1%) lost 1 line of BCVA; 7 eyes (17.9%) gained at least 1 line. One eye (2.6%) showed a change in SE greater than 1.0 D over the follow-up period. The mean ECL was 10.9%, but morphologic analysis suggested no additional damage caused by LASIK over that produced by phakic IOL surgery. Overall patient satisfaction was high.
The combination of Artisan phakic IOL implantation and LASIK safely, predictably, and effectively reduced high hyperopia. A loss of 1 line of BCVA should be expected in about one third of eyes implanted with this IOL. Halos and glare at night remain a potential problem.
评估在植入阿蒂桑有晶状体眼人工晶状体(IOL)后再行准分子原位角膜磨镶术(LASIK)矫正高度远视的安全性、有效性、可预测性、稳定性、并发症及患者满意度。
西班牙阿利坎特市阿利坎特眼科研究所。
这项前瞻性试验纳入了39只眼,术前平均等效球镜度(SE)为7.39屈光度(D)±1.30(标准差),柱镜度数在0至 -4.25 D之间。植入用于远视的阿蒂桑虹膜固定型有晶状体眼IOL(Ophtec),并在6至8个月后进行LASIK手术。记录最佳矫正视力(BCVA)、未矫正视力(UCVA)、屈光、内皮细胞丢失(ECL)、内皮形态学分析及患者满意度。最短随访时间为12个月。
1年后,37只眼(94.9%)的屈光状态在正视眼±1.00 D范围内,31只眼(79.5%)在±0.50 D范围内。35只眼(89.7%)的UCVA达到0.5或更好。有晶状体眼IOL植入后BCVA有统计学意义的下降,但LASIK术后这种影响得到纠正。9只眼(23.1%)的BCVA下降了1行;7只眼(17.9%)至少提高了1行。1只眼(2.6%)在随访期间SE变化大于1.0 D。平均ECL为10.9%,但形态学分析表明LASIK并未比对有晶状体眼IOL手术造成的损伤产生额外损害。总体患者满意度较高。
阿蒂桑有晶状体眼IOL植入联合LASIK安全、可预测且有效地降低了高度远视。植入这种IOL的眼中约三分之一应预期会出现BCVA下降1行的情况。夜间光晕和眩光仍是一个潜在问题。